Clinical prognostic analysis on 69 cases of adult Hodgkin lymphoma

doi:10.3969/j.issn.1004-583X.2016.01.015

Abstract

Abstract: Objective To explore the clinical characteristics and prognosis of Hodgkin lymphoma(HL).Methods The clinical data of 69 adult patients with HL treated at our hospital from Jan. 2004 to Dec. 2014 were analyzed retrospectively,analyzing the clinical characteristics with prognosis.Results ①50 patients (72.5%) had cervical lymph nodes involvement in the pre-treatment evaluation.Pathological study revealed that mixed cellularity was most common.②The response rate was 76.8%(53/69). The rates of 5-years overall survival rate and failure free survival were 80.0% and 72.0%.③Kaplan-Meier single-factor analysis showed that age,clinical staging,extra nodal tissues involvement, splenomegaly,International Prognostic Index(IPI) grouping, hemoglobin, first-line chemotherapy regimens,chemotherapy course, remission were the main factors influencing the survival (P<0.05).④Cox model multivariate analysis indicated that remission was the main factor affecting the survival (P<0.05).Conclusion Cervical lymph node was the most common involvement site with HL. Remission was the independent prognosis risk factor for HL.

Key words: lymphoma,hodgkin, prognosis, signs and symptoms

CLC Number:

R733.41

Zhao Weihua, Xu Haiping, Peng Zhigang, Yao Yibing, Jiang Yanfeng, Ma Jie. Clinical prognostic analysis on 69 cases of adult Hodgkin lymphoma[J]. Clinical Focus, 2016, 31(1): 59-62.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.015

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/59

References

[1] 董颖,陈赛娟.淋巴瘤的流行病学[M]//沈志祥,朱雄增.恶性淋巴瘤.2版.北京:人民卫生出版社,2011:25-26.
[2] Jaffe ES, Harris HL, Stein M, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World health organization classification of tumor[M].Lyon:IARC Press, 2001:150-153.
[3] Federico M,Luminari S,Iannitto E,et al.ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma:results from the HD2000 Gruppo Italiato perlo Studio dei Linfomi Trital[J]. J Clin Oncol,2009,27(1):805-811.
[4] Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting[J]. J Clin Oncol,1989,7(11):1630-1666.
[5] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol,2007,25(5):579-586.
[6] 李小秋,李甘地,高子芬,等.中国淋巴瘤亚型分布:国内多中心性病例10002例分析[J].诊断学理论与实践,2012,11(2):111-115.
[7] Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244[J]. J Clin Oncol, 2009, 27(32): 5390-5396.
[8] 谭文勇, 胡德胜, 宋启斌, 等. 早期霍奇金淋巴瘤的预后多因素分析[J]. 肿瘤, 2008, 28(6): 510-513.
[9] Provencio M, Espaa P, Milln I, et al. Prognostic factors in Hodgkin's disease[J]. Leuk Lymphoma, 2004, 45(6): 1133-1139.
[10] Shipp M. Prognostic factors in non-Hodgkin's lymphoma[J]. Curr Opin Oncol,1992, 4(5): 856-862.
[11] 赵春, 张尚福, 李甘地. 143例霍奇金淋巴瘤的WHO分类草案应用及临床病理分析[J]. 临床与实验病理学杂志, 2000, 16(2): 96-99.
[12] Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned[J]. N Engl J Med, 2011, 365(3): 203-212.
[13] 付晓红,陈碧君,马萍,等. 霍奇金淋巴瘤综合治疗的临床分析[J]. 实用癌症杂志, 2014, 29(1): 93-96.
[14] 黄进,钟美佐,舒毅刚,等. 霍奇金淋巴瘤121例临床预后因素分析[J].中国现代医学杂志,2005,15(8):1256-1259.
[15] Tubiana M, Henry M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987[J]. Blood, 1989, 73(1): 47-56.
[16] Carde P, Burgers JM, Henry M, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors[J]. J Clinical Oncol, 1988, 6(2): 239-252.
[17] Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease[J]. N Engl J Med, 1998, 339(21): 1506-1514.
[18] 陶云霞,康愫意,孙剑笠,等. 晚期霍奇金淋巴瘤115例临床疗效总结与预后分析[J].癌症进展,2013,11(3):259-263.
[19] Russo F, Lastoria S, Svanera G, et al. Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma[J]. Leuk Lymphoma,2007, 48(4): 723-730.
[20] Bonnet C, Beguin Y, Fassotte MF, et al. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma[J]. Eur J Haematol, 2007, 78(5): 399-404.